€9.70
0.89% day before yesterday
L&S, Jul 05, 10:53 pm CET
ISIN
US7291391057
Symbol
PLRX
Sector
Industry

Pliant Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Pliant Therapeutics Inc Classifications & Recommendation:

Buy
100%

Pliant Therapeutics Inc Price Target

Target Price $41.82
Price $10.52
Potential
Number of Estimates 11
11 Analysts have issued a price target Pliant Therapeutics Inc 2025 . The average Pliant Therapeutics Inc target price is $41.82. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 13 Analysts recommend Pliant Therapeutics Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Pliant Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Pliant Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 1.58 1.83
83.69% 15.54%
EBITDA Margin -11,537.97% -12,420.42%
805.14% 7.65%
Net Margin -10,498.73% -11,502.77%
473.66% 9.56%

11 Analysts have issued a sales forecast Pliant Therapeutics Inc 2024 . The average Pliant Therapeutics Inc sales estimate is

$1.8m
Unlock
. This is
630.20% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$15.0m 5,900.00%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $1.6m 83.69%
2024
$1.8m 15.54%
Unlock
2025
$7.6m 314.02%
Unlock
2026
$6.1m 19.33%
Unlock
2027
$46.5m 662.16%
Unlock
2028
$166m 257.67%
Unlock

2 Analysts have issued an Pliant Therapeutics Inc EBITDA forecast 2024. The average Pliant Therapeutics Inc EBITDA estimate is

$-227m
Unlock
. This is
18.51% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-213m 11.08%
Unlock
, the lowest is
$-241m 25.93%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-182m 47.59%
2024
$-227m 24.37%
Unlock
2025
$-255m 12.49%
Unlock
2026
$-300m 17.66%
Unlock

EBITDA Margin

2023 -11,537.97% 805.14%
2024
-12,420.42% 7.65%
Unlock
2025
-3,374.46% 72.83%
Unlock
2026
-4,922.09% 45.86%
Unlock

4 Pliant Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Pliant Therapeutics Inc net profit estimate is

$-210m
Unlock
. This is
21.72% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-199m 15.39%
Unlock
, the lowest is
$-229m 33.01%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-166m 6.46%
2024
$-210m 26.59%
Unlock
2025
$-233m 11.13%
Unlock
2026
$-221m 5.49%
Unlock
2027
$-221m 0.10%
Unlock
2028
$-141m 36.06%
Unlock

Net Margin

2023 -10,498.73% 473.66%
2024
-11,502.77% 9.56%
Unlock
2025
-3,087.62% 73.16%
Unlock
2026
-3,617.69% 17.17%
Unlock
2027
-475.12% 86.87%
Unlock
2028
-84.93% 82.12%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.75 -3.48
6.46% 26.55%
P/E negative
EV/Sales 113.34

4 Analysts have issued a Pliant Therapeutics Inc forecast for earnings per share. The average Pliant Therapeutics Inc <a href=/blog/eps>EPS is

$-3.48
Unlock
. This is
21.68% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is
$-3.30 15.38%
Unlock
, the lowest is
$-3.80 32.87%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.75 6.46%
2024
$-3.48 26.55%
Unlock
2025
$-3.87 11.21%
Unlock
2026
$-3.66 5.43%
Unlock
2027
$-3.66 0.00%
Unlock
2028
$-2.34 36.07%
Unlock

P/E ratio

Current -3.68 47.80%
2024
-3.02 17.93%
Unlock
2025
-2.72 9.93%
Unlock
2026
-2.88 5.88%
Unlock
2027
-2.87 0.35%
Unlock
2028
-4.50 56.79%
Unlock

Based on analysts' sales estimates for 2024, the Pliant Therapeutics Inc stock is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of

113.34
Unlock
and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of
347.66
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 827.60 1,486.05%
2024
113.34 86.30%
Unlock
2025
27.38 75.85%
Unlock
2026
33.94 23.97%
Unlock
2027
4.45 86.88%
Unlock
2028
1.24 72.04%
Unlock

P/S ratio

Current 2,538.52 2,213.75%
2024
347.66 86.30%
Unlock
2025
83.97 75.85%
Unlock
2026
104.09 23.97%
Unlock
2027
13.66 86.88%
Unlock
2028
3.82 72.04%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today